Ms. magazine  -- more than a magazine a movement

SIGN UP FOR MS. DIGEST, JOBS, NEWS AND ALERTS

FEMINIST WIRE NEWSBRIEFS

ABOUT
SEE CURRENT ISSUE
SHOP MS. STORE
MS. IN THE CLASSROOM
FEMINIST DAILY WIRE
FEMINIST RESOURCES
PRESS
JOBS AT MS.
READ BACK ISSUES
CONTACT
RSS (XML)
 
feminist wire | daily newsbriefs

March-30-10

Court Rules Against Patents on Breast Cancer Genes

A New York District Court judge ruled yesterday that patents on the human BRCA1 and BRCA2 genes, which are associated with breast and ovarian cancer, are invalid because the patents were "directed to a law of nature and were therefore improperly granted." The ruling (see PDF) did not consider claims that the patents are unconstitutional.

Myriad Genetics and the University of Utah Research Foundation currently hold patents on the BRCA1 and BRCA 2 genes and have exclusive rights to perform diagnostic testing on the genes. The patents allow Myriad to restrict outside research on the genes and monopolize predictive cancer tests, for which the company charges $3000, that check for mutations in an individual's genes.

Judge Robert Sweet ruled that "the isolation of the BRCA1 and BRCA2 DNA, while requiring technical skill and considerable labor, was simply the application of techniques well-known to those skilled in the art...The identification of the BRCA1 and BRCA2 gene sequences is unquestionably a valuable scientific achievement for which Myriad deserves recognition, but that is not the same as concluding that it is something for which they are entitled to a patent."

The American Civil Liberties Union (ACLU) and the Public Patent Foundation originally filed the lawsuit last year on the grounds that genes cannot be patented because they are "products of nature" and that the patents violate the First Amendment by restricting research. Plaintiffs included individual women, women's health groups, and science associations and professionals. Arguments in the case were heard in February.

ACLU staff attorney Chris Hansen said in a press release that the "ruling is a victory for the free flow of ideas in scientific research. The human genome, like the structure of blood, air, or water, was discovered, not created. There is an endless amount of information on genes that begs for further discovery, and gene patents put up unacceptable barriers to the free exchange of ideas."

The current lawsuit is the first to challenge gene patents as a civil rights violation and its outcome could have a far-reaching impact in genetic research as 20 percent of all human genes are currently patented; including those associated with Alzheimer's disease, muscular dystrophy, and asthma. Law professor Kenneth Chahine, who filed an amicus brief in support of Myriad´┐Żs case, told the New York Times, "If a decision like this were upheld, it would have a pretty significant impact on the future of medicine...The industry is going to have to get more creative about how to retain exclusivity and attract capital in the face of potentially weaker patent protection."

According to the National Cancer Institute at the National Institutes of Health, women with BRCA1 or BRCA2 are 3 to 7 times more likely to develop breast or ovarian cancer than other women.

Media Resources: ACLU Press Release 3/29/10; New York Times 3/30/10; Feminist Daily Newswire 2/2/10; National Cancer Institute; US District Court Ruling 3/29/10


© Feminist Majority Foundation, publisher of Ms. magazine

If you liked this story, consider making a tax-deductible donation to support Ms. magazine.

 

 

Send to a Friend
Their
Your
Comments
(optional)


More Feminist News

10/31/2014 Federal Judge Exempts Another Catholic University from Birth Control Coverage - A federal judge ruled Tuesday that Ave Maria University, a Catholic university in Florida, does not have to comply with federal rules meant to ensure that covered employees can exercise their right to obtain birth control at no cost. The Affordable Care Act requires all new health insurance plans to cover all FDA-approved contraceptives - such as the pill, emergency contraceptives, and IUDs - without charging co-pays, deductibles or co-insurance. . . .
 
10/31/2014 Women of Color in Tennessee Are United in Opposition to Amendment 1 - Just days before the general election in Tennessee, a coalition of community leaders, clergy, and advocates led a press conference encouraging women of color to vote no on Amendment 1, a dangerous and far-reaching measure on the state's ballot. SisterReach, a grassroots organization focused on "empowering, organizing, and mobilizing women and girls in the community around their reproductive and sexual health to make informed decisions about themselves," organized the press conference "to call attention to the unique concerns Black and poor communities throughout Shelby County and across the state of Tennessee face on a daily basis" and to emphasize how the upcoming election "could further limit [black women's] reproductive, economic, political, and social autonomy." "We assemble today to impress upon black women and women of color, many of whom are heads of households, to get out and vote," said SisterReacher Founder and CEO Cherisse Scott at the event. SisterReach has been educating voters about the particularly dangerous impact of Amendment 1 on women of color. . . .
 
10/30/2014 Medication Abortion Access Threatened by Oklahoma Court Ruling - An Oklahoma state district court judge has refused to block a state law restricting medication abortion, clearing the way for the law to go into affect on November 1. The Oklahoma Coalition for Reproductive Justice, together with a local abortion clinic in Tulsa, challenged HB 2684 in September, arguing that the law was an unconstitutional restriction on non-surgical abortion in the earliest weeks of pregnancy. . . .